{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:37:18Z","timestamp":1763037438744,"version":"3.37.3"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T00:00:00Z","timestamp":1590451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100002383","name":"King Saud University","doi-asserted-by":"publisher","award":["RSP-2019\/74"],"award-info":[{"award-number":["RSP-2019\/74"]}],"id":[{"id":"10.13039\/501100002383","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Osteomyelitis is one of the most challenging infectious diseases to treat and is associated with a significant burden to healthcare systems. There are limited available therapeutic options to treat osteomyelitis caused by Gram-positive pathogens and these are not without limitations. Dalbavancin is a long-acting lipoglycopeptide, approved for the treatment of acute bacterial skin and skin structure infections caused by designated susceptible strains of Gram-positive microorganisms. It demonstrated promising pharmacokinetic\/pharmacodynamic properties and safety data to be considered for the treatment of bone infections. However, information on the effectiveness and safety of dalbavancin in the treatment of invasive Gram-positive infections, such as osteomyelitis, is very limited. In this review, we describe the novel characteristics and potential utility of dalbavancin in the treatment of osteomyelitis and summarize its long-term clinical outcomes from published case reports, series and comparative studies.<\/jats:p>","DOI":"10.1093\/jac\/dkaa188","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T19:09:49Z","timestamp":1587582589000},"page":"2717-2722","source":"Crossref","is-referenced-by-count":18,"title":["Dalbavancin for the management of osteomyelitis: a major step forward?"],"prefix":"10.1093","volume":"75","author":[{"given":"Thamer A","family":"Almangour","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, King Saud University, PO Box 2457, Riyadh 11451, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9492-9483","authenticated-orcid":false,"given":"Abdullah A","family":"Alhifany","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, Umm Al-Qura University, PO Box 13578, Makkah 21955, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,5,26]]},"reference":[{"key":"2020101416050204600_dkaa188-B1","first-page":"1027","article-title":"Diagnosis and management of osteomyelitis","volume":"84","author":"Hatzenbuehler","year":"2011","journal-title":"Am Fam Physician"},{"key":"2020101416050204600_dkaa188-B2","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/jac\/dkh191","article-title":"Antibiotic treatment of Gram-positive bone and joint infections","volume":"53","author":"Darley","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"2020101416050204600_dkaa188-B3","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMcp0910753","article-title":"Clinical practice. Vertebral osteomyelitis","volume":"362","author":"Zimmerli","year":"2010","journal-title":"N Engl J Med"},{"key":"2020101416050204600_dkaa188-B4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diagmicrobio.2018.10.007","article-title":"Dalbavancin for the management of gram-positive osteomyelitis: effectiveness and potential utility","volume":"93","author":"Almangour","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"year":"2014","key":"2020101416050204600_dkaa188-B5"},{"key":"2020101416050204600_dkaa188-B6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40121-019-0247-0","article-title":"Dalbavancin use in vulnerable patients receiving outpatient parenteral antibiotic therapy for invasive Gram-positive infections","volume":"8","author":"Bork","year":"2019","journal-title":"Infect Dis Ther"},{"key":"2020101416050204600_dkaa188-B7","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-duration dosing and distribution of dalbavancin into bone and articular tissue","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020101416050204600_dkaa188-B8","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1128\/AAC.00020-07","article-title":"Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits","volume":"51","author":"Solon","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2020101416050204600_dkaa188-B9","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.diagmicrobio.2012.11.024","article-title":"Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011","volume":"75","author":"Jones","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020101416050204600_dkaa188-B10","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ijantimicag.2017.12.011","article-title":"Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016)","volume":"51","author":"Pfaller","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2020101416050204600_dkaa188-B11","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1128\/AAC.32.9.1320","article-title":"Vancomycin concentrations in infected and noninfected human bone","volume":"32","author":"Graziani","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"key":"2020101416050204600_dkaa188-B12","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1128\/AAC.01264-06","article-title":"In vivo pharmacodynamic activity of the glycopeptide dalbavancin","volume":"51","author":"Andes","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2020101416050204600_dkaa188-B13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40264-015-0374-9","article-title":"Safety of dalbavancin in the treatment of skin and skin structure infections: a pooled analysis of randomized, comparative studies","volume":"39","author":"Dunne","year":"2016","journal-title":"Drug Saf"},{"key":"2020101416050204600_dkaa188-B14","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1093\/cid\/civ482","article-title":"Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults","volume":"61","author":"Berbari","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020101416050204600_dkaa188-B15","doi-asserted-by":"crossref","first-page":"S336","DOI":"10.1093\/ofid\/ofz360.822","article-title":"Evaluation of standardized dalbavancin use to facilitate early hospital discharge for patients inappropriate for outpatient parenteral antibiotic therapy","volume":"6 Suppl 2","author":"Shihadeh","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2020101416050204600_dkaa188-B16","doi-asserted-by":"crossref","first-page":"S709","DOI":"10.1093\/ofid\/ofy210.2033","article-title":"Healthcare resource utilization for high-risk patients treated with dalbavancin in physician office infusion centers (POICs)","volume":"5 Suppl 1","author":"Luu","year":"2018","journal-title":"Open Forum Infect Dis"},{"volume":"6","article-title":"Long-acting lipoglycopeptides: \u201clineless antibiotics\" for serious infections in persons who use drugs","author":"Morrisette","key":"2020101416050204600_dkaa188-B17"},{"key":"2020101416050204600_dkaa188-B18","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","article-title":"Dalbavancin in the treatment of different gram-positive infections: a real-life experience","volume":"51","author":"Bouza","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2020101416050204600_dkaa188-B19","first-page":"A280","article-title":"Off-label use of dalbavancin in gram-positive infections: effectiveness, safety and cost in clinical practice","volume":"26","author":"Chamorro-De Vega","year":"2019","journal-title":"Eur J Hosp Pharm"},{"key":"2020101416050204600_dkaa188-B20","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1093\/jac\/dkz162","article-title":"On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections","volume":"74","author":"Morrisette","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2020101416050204600_dkaa188-B21","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ijantimicag.2019.08.007","article-title":"Dalbavancin use in an academic medical centre and associated cost savings","volume":"54","author":"Streifel","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2020101416050204600_dkaa188-B22","first-page":"Doc03","article-title":"Potential savings through single-dose intravenous dalbavancin in long-term MRSA infection treatment: a health economic analysis using German DRG data","volume":"7","author":"Wilke","year":"2019","journal-title":"GMS Infect Dis"},{"key":"2020101416050204600_dkaa188-B23","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40261-020-00891-w","article-title":"Budget impact analysis of dalbavancin in the treatment of acute bacterial skin and skin structure infections in three European countries","volume":"40","author":"Marcellusi","year":"2020","journal-title":"Clin Drug Investig"},{"key":"2020101416050204600_dkaa188-B24","doi-asserted-by":"crossref","first-page":"ofy331","DOI":"10.1093\/ofid\/ofy331","article-title":"Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety","volume":"6","author":"Rappo","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2020101416050204600_dkaa188-B25","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1056\/NEJMoa1710926","article-title":"Oral versus intravenous antibiotics for bone and joint infection","volume":"380","author":"Li","year":"2019","journal-title":"N Engl J Med"},{"key":"2020101416050204600_dkaa188-B26","doi-asserted-by":"crossref","first-page":"ofz028","DOI":"10.1093\/ofid\/ofz028","article-title":"Dalbavancin as secondary therapy for serious Staphylococcus aureus infections in a vulnerable patient population","volume":"6","author":"Bryson-Cahn","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2020101416050204600_dkaa188-B27","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.12659\/AJCR.905930","article-title":"Multiple weekly dalbavancin dosing for the treatment of native vertebral osteomyelitis caused by methicillin-resistant Staphylococcus aureus: a case report","volume":"18","author":"Almangour","year":"2017","journal-title":"Am J Case Rep"},{"key":"2020101416050204600_dkaa188-B28","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ijid.2019.02.013","article-title":"Multicenter clinical experience of real life dalbavancin use in gram-positive infections","volume":"81","author":"Wunsch","year":"2019","journal-title":"Int J Infect Dis"},{"key":"2020101416050204600_dkaa188-B29","doi-asserted-by":"crossref","first-page":"e02280","DOI":"10.1128\/AAC.02280-18","article-title":"Safety and efficacy of prolonged use of dalbavancin in bone and joint infections","volume":"63","author":"Morata","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2020101416050204600_dkaa188-B30","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s15010-019-01354-x","article-title":"Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection","volume":"47","author":"Tobudic","year":"2019","journal-title":"Infection"},{"key":"2020101416050204600_dkaa188-B31","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jsps.2020.02.007","article-title":"Dalbavancin versus standard of care for the treatment of osteomyelitis in adults: a retrospective matched cohort study","volume":"28","author":"Almangour","year":"2020","journal-title":"Saudi Pharm J"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/10\/2717\/33885320\/dkaa188.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/10\/2717\/33885320\/dkaa188.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T08:28:35Z","timestamp":1615364915000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/75\/10\/2717\/5846242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,26]]},"references-count":31,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,5,26]]},"published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa188","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2020,5,26]]}}}